Invivyd, Inc. (NASDAQ:IVVD) Given Average Rating of "Hold" by Analysts

Key Points

• Analysts rate Invivyd “Hold” on average: Of six analysts, three recommend buying, two rate it a hold, and one recommends selling. The average 12-month price target is $8.00.
• Invivyd shares opened at $0.90, versus a 52-week range of $0.53 to $3.07. The company reported a quarterly loss of $0.14 per share, missing estimates by $0.03, while revenue of $14.29 million was slightly below expectations.
• Insider selling has continued: An insider sold 37,256 shares worth about $26,824 to cover tax withholding, while insiders sold 228,024 shares in total during the last quarter.

Invivyd, Inc. (NASDAQ:IVVD - Get Free Report) has been given an average recommendation of "Hold" by the six research firms that are presently covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating, two have assigned a hold rating and three have assigned a buy rating to the company. The average 1 year target price among analysts that have updated their coverage on the stock in the last year is $8.00.

A number of research analysts have recently issued reports on the company. HC Wainwright reaffirmed a "buy" rating on shares of Invivyd in a research note on Tuesday, August 18th. Weiss Ratings cut Invivyd from a "sell (d-)" rating to a "sell (e+)" rating in a report on Monday. Cantor Fitzgerald restated an "overweight" rating on shares of Invivyd in a research report on Thursday. BTIG Research restated a "buy" rating on shares of Invivyd in a research report on Tuesday, July 7th. Finally, Wall Street Zen cut Invivyd from a "hold" rating to a "strong sell" rating in a research note on Saturday, May 16th.

Invivyd Stock Performance

Shares of Invivyd stock opened at $0.90 on Friday. Invivyd has a 52-week low of $0.53 and a 52-week high of $3.07. The company has a fifty day moving average of $0.78 and a 200-day moving average of $1.19. The stock has a market capitalization of $265.31 million, a price-to-earnings ratio of -2.73 and a beta of 0.71.

Invivyd (NASDAQ:IVVD - Get Free Report) last issued its earnings results on Thursday, August 13th. The company reported ($0.14) EPS for the quarter, missing analysts' consensus estimates of ($0.11) by ($0.03). The business had revenue of $14.29 million during the quarter, compared to analysts' expectations of $14.40 million. Invivyd had a negative return on equity of 59.73% and a negative net margin of 183.90%. On average, equities research analysts forecast that Invivyd will post -0.51 earnings per share for the current fiscal year.

Insider Activity

In related news, insider Jill Andersen sold 37,256 shares of Invivyd stock in a transaction on Monday, August 17th. The shares were sold at an average price of $0.72, for a total value of $26,824.32. Following the transaction, the insider directly owned 314,480 shares of the company's stock, valued at $226,425.60. The trade was a 10.59% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold a total of 228,024 shares of company stock valued at $176,540 in the last quarter. 12.25% of the stock is currently owned by company insiders.

Institutional Trading of Invivyd

A number of institutional investors have recently modified their holdings of the company. Chicago Partners Investment Group LLC bought a new stake in shares of Invivyd in the first quarter worth about $25,000. Bronte Capital Management Pty Ltd. bought a new position in shares of Invivyd during the fourth quarter valued at approximately $27,000. DRW Securities LLC purchased a new stake in Invivyd in the fourth quarter worth $27,000. ProShare Advisors LLC purchased a new stake in Invivyd in the fourth quarter worth $30,000. Finally, State of Wyoming bought a new stake in Invivyd in the fourth quarter valued at $30,000. 70.36% of the stock is currently owned by hedge funds and other institutional investors.

Invivyd Company Profile

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering. Its pipeline includes PEMGRADA (pemivibart) injection, a half-life extended investigational monoclonal antibody (mAb) for the prevention of COVID-19 in adults and adolescents; VYD2311, an mAb candidate which is in preclinical studies for the prevention or treatment for COVID-19; and adintrvimab, that is in phase 3 clinical trials for the prevention or treatment of COVID-19.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source